
Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Research Report 2024
Description
Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Research Report 2024
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
Highlights
The global Amyotrophic Lateral Sclerosis (ALS) Treatment market is projected to reach US$ million by 2030 from an estimated US$ million in 2024, at a CAGR of % during 2025 and 2030.
GlobalAmyotrophic Lateral Sclerosis (ALS) Treatment key players include Mitsubishi Tanabe Pharma, Sanofi, etc. Global top two manufacturers hold a share over 80%.
North America is the largest market, with a share about 60%, followed by Japan, and Europe, both have a share over 20 percent.
In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%. And in terms of application, the largest application is Hospital, followed by Drugs Store, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Amyotrophic Lateral Sclerosis (ALS) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Amyotrophic Lateral Sclerosis (ALS) Treatment.
The Amyotrophic Lateral Sclerosis (ALS) Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Amyotrophic Lateral Sclerosis (ALS) Treatment market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Amyotrophic Lateral Sclerosis (ALS) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Product Type Insights
Global markets are presented by Amyotrophic Lateral Sclerosis (ALS) Treatment type, along with growth forecasts through 2030. Estimates on revenue are based on the price in the supply chain at which the Amyotrophic Lateral Sclerosis (ALS) Treatment are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2019-2024) and forecast period (2025-2030).
Amyotrophic Lateral Sclerosis (ALS) Treatment segment by Type
Riluzole
Edaravone (Radicava)
Other
Application Insights
This report has provided the market size (revenue data) by application, during the historical period (2019-2024) and forecast period (2025-2030).
This report also outlines the market trends of each segment and consumer behaviors impacting the Amyotrophic Lateral Sclerosis (ALS) Treatment market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Amyotrophic Lateral Sclerosis (ALS) Treatment market.
Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Application
Hospital
Drugs Store
Other
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2019-2030.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2023 because of the base year, with estimates for 2024 and forecast revenue for 2030.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Amyotrophic Lateral Sclerosis (ALS) Treatment market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyotrophic Lateral Sclerosis (ALS) Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Amyotrophic Lateral Sclerosis (ALS) Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Amyotrophic Lateral Sclerosis (ALS) Treatment industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyotrophic Lateral Sclerosis (ALS) Treatment.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Table of Contents
85 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment by Type
- 2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
- 1.2.2 Riluzole
- 1.2.3 Edaravone (Radicava)
- 1.2.4 Other
- 2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment by Application
- 2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
- 2.3.2 Hospital
- 2.3.3 Drugs Store
- 2.3.4 Other
- 2.4 Assumptions and Limitations
- 3 Amyotrophic Lateral Sclerosis (ALS) Treatment Breakdown Data by Type
- 3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Type (2019-2024)
- 3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Type (2025-2030)
- 4 Amyotrophic Lateral Sclerosis (ALS) Treatment Breakdown Data by Application
- 4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Application (2019-2024)
- 4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Application (2019-2024)
- 5 Global Growth Trends
- 5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Perspective (2019-2030)
- 5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Growth Trends by Region
- 5.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region: 2019 VS 2023 VS 2030
- 5.2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Region (2019-2024)
- 5.2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Region (2025-2030)
- 5.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Dynamics
- 5.3.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Trends
- 5.3.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers
- 5.3.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Challenges
- 5.3.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints
- 6 Market Competitive Landscape by Players
- 6.1 Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Revenue
- 6.1.1 Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Revenue (2019-2024)
- 6.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Players (2019-2024)
- 6.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Players Ranking, 2022 VS 2023 VS 2024
- 6.3 Global Key Players of Amyotrophic Lateral Sclerosis (ALS) Treatment Head office and Area Served
- 6.4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Players, Product Type & Application
- 6.5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Players, Date of Enter into This Industry
- 6.6 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
- 7 North America
- 7.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2019-2030)
- 7.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 7.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2019-2024)
- 7.4 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2025-2030)
- 7.5 United States
- 7.6 Canada
- 8 Europe
- 8.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2019-2030)
- 8.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 8.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2019-2024)
- 8.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2025-2030)
- 7.4 Germany
- 7.5 France
- 7.6 U.K.
- 7.7 Italy
- 7.8 Russia
- 7.9 Nordic Countries
- 9 Asia-Pacific
- 9.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2019-2030)
- 9.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 9.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2019-2024)
- 9.4 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2025-2030)
- 8.4 China
- 8.5 Japan
- 8.6 South Korea
- 8.7 Southeast Asia
- 8.8 India
- 8.9 Australia
- 10 Latin America
- 10.1 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2019-2030)
- 10.2 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 10.3 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2019-2024)
- 10.4 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2025-2030)
- 9.4 Mexico
- 9.5 Brazil
- 11 Middle East & Africa
- 11.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2019-2030)
- 11.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 11.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2019-2024)
- 11.4 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2025-2030)
- 10.4 Turkey
- 10.5 Saudi Arabia
- 10.6 UAE
- 12 Players Profiled
- 11.1 Mitsubishi Tanabe Pharma
- 11.1.1 Mitsubishi Tanabe Pharma Company Detail
- 11.1.2 Mitsubishi Tanabe Pharma Business Overview
- 11.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
- 11.1.4 Mitsubishi Tanabe Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022)
- 11.1.5 Mitsubishi Tanabe Pharma Recent Development
- 11.2 Sanofi
- 11.2.1 Sanofi Company Detail
- 11.2.2 Sanofi Business Overview
- 11.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
- 11.2.4 Sanofi Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022)
- 11.2.5 Sanofi Recent Development
- 11.3 Mylan Pharma
- 11.3.1 Mylan Pharma Company Detail
- 11.3.2 Mylan Pharma Business Overview
- 11.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
- 11.3.4 Mylan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022)
- 11.3.5 Mylan Pharma Recent Development
- 11.4 Apotex
- 11.4.1 Apotex Company Detail
- 11.4.2 Apotex Business Overview
- 11.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
- 11.4.4 Apotex Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022)
- 11.4.5 Apotex Recent Development
- 11.5 Glemark Generics
- 11.5.1 Glemark Generics Company Detail
- 11.5.2 Glemark Generics Business Overview
- 11.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
- 11.5.4 Glemark Generics Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022)
- 11.5.5 Glemark Generics Recent Development
- 11.6 Covis Pharma
- 11.6.1 Covis Pharma Company Detail
- 11.6.2 Covis Pharma Business Overview
- 11.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
- 11.6.4 Covis Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022)
- 11.6.5 Covis Pharma Recent Development
- 11.7 Sun Pharma
- 11.7.1 Sun Pharma Company Detail
- 11.7.2 Sun Pharma Business Overview
- 11.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
- 11.7.4 Sun Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022)
- 11.7.5 Sun Pharma Recent Development
- 11.8 Lunan Pharma
- 11.8.1 Lunan Pharma Company Detail
- 11.8.2 Lunan Pharma Business Overview
- 11.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
- 11.8.4 Lunan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022)
- 11.8.5 Lunan Pharma Recent Development
- 13 Report Conclusion
- 14 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US$ Million)
- Table 4. Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US$ Million)
- Table 5. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2019-2024) & (US$ Million)
- Table 6. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2019-2024)
- Table 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
- Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2025-2030)
- Table 9. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2019-2024) & (US$ Million)
- Table 10. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2019-2024)
- Table 11. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
- Table 12. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2025-2030)
- Table 13. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
- Table 14. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2019-2024) & (US$ Million)
- Table 15. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region (2019-2024)
- Table 16. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
- Table 17. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region (2025-2030)
- Table 18. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Trends
- Table 19. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers
- Table 20. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Challenges
- Table 21. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints
- Table 22. Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Manufacturers by Revenue (US$ Million) & (2019-2024)
- Table 23. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Manufacturers (2019-2024)
- Table 24. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Manufacturers Ranking, 2022 VS 2023 VS 2024
- Table 25. Global Key Players of Amyotrophic Lateral Sclerosis (ALS) Treatment, Headquarters and Area Served
- Table 26. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Manufacturers, Product Type & Application
- Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 28. Global Amyotrophic Lateral Sclerosis (ALS) Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
- Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
- Table 30. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030 (US$ Million)
- Table 31. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2019-2024) & (US$ Million)
- Table 32. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2025-2030) & (US$ Million)
- Table 33. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030 (US$ Million)
- Table 34. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2019-2024) & (US$ Million)
- Table 35. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2025-2030) & (US$ Million)
- Table 36. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030 (US$ Million)
- Table 37. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2019-2024) & (US$ Million)
- Table 38. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2025-2030) & (US$ Million)
- Table 39. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030 (US$ Million)
- Table 40. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2019-2024) & (US$ Million)
- Table 41. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2025-2030) & (US$ Million)
- Table 42. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030 (US$ Million)
- Table 43. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2019-2024) & (US$ Million)
- Table 44. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2025-2030) & (US$ Million)
- Table 45. Mitsubishi Tanabe Pharma Company Detail
- Table 46. Mitsubishi Tanabe Pharma Business Overview
- Table 47. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product
- Table 48. Mitsubishi Tanabe Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022) & (US$ Million)
- Table 49. Mitsubishi Tanabe Pharma Recent Development
- Table 50. Sanofi Company Detail
- Table 51. Sanofi Business Overview
- Table 52. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product
- Table 53. Sanofi Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022) & (US$ Million)
- Table 54. Sanofi Recent Development
- Table 55. Mylan Pharma Company Detail
- Table 56. Mylan Pharma Business Overview
- Table 57. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product
- Table 58. Mylan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022) & (US$ Million)
- Table 59. Mylan Pharma Recent Development
- Table 60. Apotex Company Detail
- Table 61. Apotex Business Overview
- Table 62. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product
- Table 63. Apotex Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022) & (US$ Million)
- Table 64. Apotex Recent Development
- Table 65. Glemark Generics Company Detail
- Table 66. Glemark Generics Business Overview
- Table 67. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product
- Table 68. Glemark Generics Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022) & (US$ Million)
- Table 69. Glemark Generics Recent Development
- Table 70. Covis Pharma Company Detail
- Table 71. Covis Pharma Business Overview
- Table 72. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product
- Table 73. Covis Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022) & (US$ Million)
- Table 74. Covis Pharma Recent Development
- Table 75. Sun Pharma Company Detail
- Table 76. Sun Pharma Business Overview
- Table 77. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product
- Table 78. Sun Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022) & (US$ Million)
- Table 79. Sun Pharma Recent Development
- Table 80. Lunan Pharma Company Detail
- Table 81. Lunan Pharma Business Overview
- Table 82. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product
- Table 83. Lunan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022) & (US$ Million)
- Table 84. Lunan Pharma Recent Development
- Table 85. Mitsubishi Tanabe Pharma Company Information
- Table 86. Mitsubishi Tanabe Pharma Business Overview
- Table 87. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2019-2024) & (US$ Million)
- Table 88. Mitsubishi Tanabe Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2019-2024) & (US$ Million) Portfolio
- Table 89. Mitsubishi Tanabe Pharma Recent Development
- Table 90. Sanofi Company Information
- Table 91. Sanofi Business Overview
- Table 92. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2019-2024) & (US$ Million)
- Table 93. Sanofi Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2019-2024) & (US$ Million) Portfolio
- Table 94. Sanofi Recent Development
- Table 95. Mylan Pharma Company Information
- Table 96. Mylan Pharma Business Overview
- Table 97. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2019-2024) & (US$ Million)
- Table 98. Mylan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2019-2024) & (US$ Million) Portfolio
- Table 99. Mylan Pharma Recent Development
- Table 100. Apotex Company Information
- Table 101. Apotex Business Overview
- Table 102. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2019-2024) & (US$ Million)
- Table 103. Apotex Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2019-2024) & (US$ Million) Portfolio
- Table 104. Apotex Recent Development
- Table 105. Glemark Generics Company Information
- Table 106. Glemark Generics Business Overview
- Table 107. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2019-2024) & (US$ Million)
- Table 108. Glemark Generics Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2019-2024) & (US$ Million) Portfolio
- Table 109. Glemark Generics Recent Development
- Table 110. Covis Pharma Company Information
- Table 111. Covis Pharma Business Overview
- Table 112. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2019-2024) & (US$ Million)
- Table 113. Covis Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2019-2024) & (US$ Million) Portfolio
- Table 114. Covis Pharma Recent Development
- Table 115. Sun Pharma Company Information
- Table 116. Sun Pharma Business Overview
- Table 117. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2019-2024) & (US$ Million)
- Table 118. Sun Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2019-2024) & (US$ Million) Portfolio
- Table 119. Sun Pharma Recent Development
- Table 120. Lunan Pharma Company Information
- Table 121. Lunan Pharma Business Overview
- Table 122. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2019-2024) & (US$ Million)
- Table 123. Lunan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2019-2024) & (US$ Million) Portfolio
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.